What is Immunovant, Inc.'s research and development expense?

Immunovant, Inc. (IMVT) reported research and development expense of $142.29M in Q1 2026.

How has Immunovant, Inc.'s research and development expense changed year-over-year?

Immunovant, Inc.'s research and development expense increased by 51.9% year-over-year, from $93.65M to $142.29M.

What is the long-term trend for Immunovant, Inc.'s research and development expense?

Over 3 years (2023 to 2026), Immunovant, Inc.'s research and development expense has grown at a 41.8% compound annual growth rate (CAGR), from $160.26M to $456.66M.

Immunovant, Inc. IMVT Research and development expense

Research and development expense at other companies

Johnson & JohnsonJNJ

$3.53B+9.4%

AbbVieABBV

——

Mirum Pharmaceuticals, Inc.MIRM

——

Neurocrine BiosciencesNBIX

——

Segments

By segment

See full

Reportable Segment$29.22M-6.2%

Other financials

Income statement

See full

Net income-$147.9M-38.9%

EPS (diluted)-$0.73-15.9%

Balance sheet

See full

Cash & equivalents$902.1M+26.4%

Total debt$72.0K-26.5%

Total equity$852.6M+20.5%

Total assets$957.0M+23.3%

Cash flow

See full

Operating cash flow-$95.1M+14.1%

CapEx$8.0K-96.0%

Free cash flow-$95.1M+14.2%

Valuation

See full

Market cap$7.26B+74.2%

Enterprise value$6.35B+89.7%

Returns & leverage

See full

Return on equity-64.8%+2.5pp

Debt / equity0×0.0×

Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunovant, Inc.'s research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunovant, Inc.'s research and development expense?: Immunovant, Inc. (IMVT) reported research and development expense of $142.29M in Q1 2026.
How has Immunovant, Inc.'s research and development expense changed year-over-year?: Immunovant, Inc.'s research and development expense increased by 51.9% year-over-year, from $93.65M to $142.29M.
What is the long-term trend for Immunovant, Inc.'s research and development expense?: Over 3 years (2023 to 2026), Immunovant, Inc.'s research and development expense has grown at a 41.8% compound annual growth rate (CAGR), from $160.26M to $456.66M.